Davis P Argersinger1, Stuart Walbridge1, Nicholas M Wetjen2, Alexander O Vortmeyer3, Tianxia Wu4, John A Butman5, John D Heiss1. 1. 1Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. 2. 2Neurological & Spinal Surgery, The Iowa Clinic, Des Moines, Iowa. 3. 3Department of Pathology, Indiana University Health Pathology Laboratory, Indianapolis, Indiana. 4. 4Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland; and. 5. 5Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Abstract
OBJECTIVE: Botulinum toxin serotype A (BoNT/A) was reported to raise the seizure threshold when injected into the seizure focus of a kindled rodent model. Delivering BoNT/A to the nonhuman primate (NHP) central nervous system via convection-enhanced delivery (CED) has not been performed. The objective of this study was to determine the toxicity and distribution characteristics of CED of BoNT/A into the NHP hippocampus and cisterna magna. METHODS: Escalating BoNT/A doses were delivered by CED into the NHP hippocampus (n = 4) and cisterna magna (n = 5) for behavioral and histological assessment and to determine the highest nonlethal dose (LD0) and median lethal dose (LD50). Hippocampal BoNT/A was coinfused with Gd-albumin, a surrogate MRI tracer. Gd-albumin and radioiodinated BoNT/A (125I-BoNT/A) were coinfused into the hippocampus of 3 additional NHPs to determine BoNT/A distribution by in vivo MRI and postmortem quantitative autoradiography. Scintillation counting of CSF assessed the flow of 125I-BoNT/A from the hippocampus to CSF postinfusion. RESULTS: LD0 and LD50 were 4.2 and 18 ng/kg, and 5 and > 5 ng/kg for the NHP hippocampus and cisterna magna, respectively. Gd-albumin and 125I-BoNT/A completely perfused the hippocampus (155-234 mm3) in 4 of 7 NHPs. Fifteen percent of BoNT/A entered CSF after hippocampal infusion. The MRI distribution volume of coinfused Gd-albumin (VdMRI) was similar to the quantitative autoradiography distribution of 125I-BoNT/A (VdQAR) (mean VdMRI = 139.5 mm3 [n = 7]; VdQAR = 134.8 mm3 [n = 3]; r = 1.00, p < 0.0001). No infusion-related toxicity was identified histologically except that directly attributable to needle placement. CONCLUSIONS: Gd-albumin accurately tracked BoNT/A distribution on MRI. BoNT/A did not produce CNS toxicity. BoNT/A LD0 exceeded 10-fold the dose administered safely to humans for cosmesis and dystonia.
OBJECTIVE: Botulinum toxin serotype A (BoNT/A) was reported to raise the seizure threshold when injected into the seizure focus of a kindled rodent model. Delivering BoNT/A to the nonhuman primate (NHP) central nervous system via convection-enhanced delivery (CED) has not been performed. The objective of this study was to determine the toxicity and distribution characteristics of CED of BoNT/A into the NHP hippocampus and cisterna magna. METHODS: Escalating BoNT/A doses were delivered by CED into the NHP hippocampus (n = 4) and cisterna magna (n = 5) for behavioral and histological assessment and to determine the highest nonlethal dose (LD0) and median lethal dose (LD50). Hippocampal BoNT/A was coinfused with Gd-albumin, a surrogate MRI tracer. Gd-albumin and radioiodinated BoNT/A (125I-BoNT/A) were coinfused into the hippocampus of 3 additional NHPs to determine BoNT/A distribution by in vivo MRI and postmortem quantitative autoradiography. Scintillation counting of CSF assessed the flow of 125I-BoNT/A from the hippocampus to CSF postinfusion. RESULTS: LD0 and LD50 were 4.2 and 18 ng/kg, and 5 and > 5 ng/kg for the NHP hippocampus and cisterna magna, respectively. Gd-albumin and 125I-BoNT/A completely perfused the hippocampus (155-234 mm3) in 4 of 7 NHPs. Fifteen percent of BoNT/A entered CSF after hippocampal infusion. The MRI distribution volume of coinfused Gd-albumin (VdMRI) was similar to the quantitative autoradiography distribution of 125I-BoNT/A (VdQAR) (mean VdMRI = 139.5 mm3 [n = 7]; VdQAR = 134.8 mm3 [n = 3]; r = 1.00, p < 0.0001). No infusion-related toxicity was identified histologically except that directly attributable to needle placement. CONCLUSIONS:Gd-albumin accurately tracked BoNT/A distribution on MRI. BoNT/A did not produce CNS toxicity. BoNT/A LD0 exceeded 10-fold the dose administered safely to humans for cosmesis and dystonia.
Entities:
Keywords:
BoNT/A = botulinum neurotoxin serotype A; CED = convection-enhanced delivery; DRE = drug-resistant epilepsy; LD0 = nonlethal dose; LD50 = median lethal dose; NHP = nonhuman primate; QAR = quantitative autoradiography; VdMRI = distribution volume on MRI; VdQAR = distribution volume on QAR; botulinum toxin serotype A; convection-enhanced delivery; hippocampus; nonhuman primates
Authors: Tung T Nguyen; Yashdip S Pannu; Cynthia Sung; Robert L Dedrick; Stuart Walbridge; Martin W Brechbiel; Kayhan Garmestani; Markus Beitzel; Alexander T Yordanov; Edward H Oldfield Journal: J Neurosurg Date: 2003-03 Impact factor: 5.115
Authors: Kathryn Adamiak Davis; Ravi Prakash Reddy Nanga; Sandhitsu Das; Stephanie H Chen; Peter N Hadar; John R Pollard; Timothy H Lucas; Russell T Shinohara; Brian Litt; Hari Hariharan; Mark A Elliott; John A Detre; Ravinder Reddy Journal: Sci Transl Med Date: 2015-10-14 Impact factor: 17.956
Authors: John D Heiss; Stuart Walbridge; Davis P Argersinger; Christopher S Hong; Abhik Ray-Chaudhury; Russell R Lonser; W Jeffrey Elias; Kareem A Zaghloul Journal: Neurosurgery Date: 2019-06-01 Impact factor: 4.654
Authors: Gregory J A Murad; Stuart Walbridge; Paul F Morrison; Kayhan Garmestani; Jeffrey W Degen; Martin W Brechbiel; Edward H Oldfield; Russell R Lonser Journal: Clin Cancer Res Date: 2006-05-15 Impact factor: 13.801